NeoGenomics Showcases RaDaR ST Molecular Residual Disease Assay at ESMO Congress 2025
核心洞察
NeoGenomics presents its RaDaR ST (搜索) circulating tumor DNA assay at ESMO Congress 2025, designed to accelerate oncology drug development through patient-specific molecular residual disease detection.
The assay uses whole-exome sequencing and advanced bioinformatics to create personalized MRD panels, delivering highly sensitive ctDNA detection from plasma samples for real-time tumor monitoring.
Three new posters from European collaborators demonstrate clinical validation of the MRD technology in interventional therapy trials, strengthening NeoGenomics' position in precision oncology partnerships.
NeoGenomics, Inc. (NASDAQ: NEO) announced the presentation of clinical data for its RaDaR ST (搜索) molecular residual disease (MRD) assay at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17-21 in Berlin, Germany. The circulating tumor DNA (ctDNA) assay is designed to accelerate and optimize oncology drug development for pharmaceutical partners.
Advanced Molecular Technology for Precision Oncology
The RaDaR ST (搜索) assay builds on NeoGenomics' established molecular capabilities, utilizing whole-exome sequencing data from tumor samples and advanced bioinformatics to create patient-specific MRD panels. The technology leverages high-depth sequencing and personalized panel design to deliver highly sensitive and specific detection of ctDNA from plasma samples, providing real-time insights into tumor dynamics and treatment response.
"We stand by our commitment to clinical validation and interventional studies utilizing NeoGenomics' MRD technology, as reflected in three new posters from our European collaborators presented at this year's ESMO congress," said Tony Zook, Chief Executive Officer. "We are excited to continue our long-standing support of drug development and interventional clinical trials, now with our RaDaR ST (搜索) assay."
Clinical Validation and Pharmaceutical Partnerships
The company is showcasing assay-relevant data, including interventional therapy trials in progress, to demonstrate how the MRD assay may benefit pharmaceutical partners. Three new posters from European collaborators presented at ESMO Congress highlight the clinical validation of NeoGenomics' MRD technology in interventional studies.
Zook emphasized the company's value proposition for pharmaceutical sponsors: "Pharmaceutical sponsors are seeking partners who can deliver both innovation and operational excellence across every stage of oncology trials. NeoGenomics meets that need with RaDaR ST (搜索), providing patient-specific insights in real time to help drive faster, more informed decisions and advance cancer research more effectively."
Strategic Positioning in Molecular Residual Disease Market
As MRD gains traction as a preferred solution to monitor responses to next-generation therapies, NeoGenomics' launch of RaDaR ST (搜索) strengthens its position as a partner to biopharma organizations seeking to advance precision oncology. The company will feature RaDaR ST and its broader oncology testing and research capabilities at booth #4012 during the congress.
NeoGenomics operates as a premier cancer diagnostics company specializing in cancer genetics testing and information services. The company offers one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms. Headquartered in Fort Myers, Florida, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.